Monthly Archives: June 2020

COVID-19: Shining the Light on Africa

Posted on by

American Journal of Tropical Medicine and Hygiene
Volume 102, Issue 6, June 2020
http://www.ajtmh.org/content/journals/14761645/102/6

 

Editorials
oa COVID-19: Shining the Light on Africa
Philip J. Rosenthal, Joel G. Breman, Abdoulaye A. Djimde, Chandy C. John, Moses R. Kamya, Rose G. F. Leke, Matshidiso R. Moeti, John Nkengasong and Daniel G. Bausch
Pages: 1145–1148
https://doi.org/10.4269/ajtmh.20-0380

 

 Reflections on Resilience during the COVID-19 Pandemic: Six Lessons from Working in Resource-Denied Settings

Posted on by

American Journal of Tropical Medicine and Hygiene
Volume 102, Issue 6, June 2020
http://www.ajtmh.org/content/journals/14761645/102/6
oa Reflections on Resilience during the COVID-19 Pandemic: Six Lessons from Working in Resource-Denied Settings
Leah Ratner, Rachel Martin-Blais, Clare Warrell and Nirmala P. Narla
Pages: 1178–1180
https://doi.org/10.4269/ajtmh.20-0274

Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings

Posted on by

American Journal of Tropical Medicine and Hygiene
Volume 102, Issue 6, June 2020
http://www.ajtmh.org/content/journals/14761645/102/6

 

Perspective Pieces
Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings
Pascale M. Abena, Eric H. Decloedt, Emmanuel Bottieau, Fatima Suleman, Prisca Adejumo, Nadia A. Sam-Agudu, Jean-Jacques Muyembe TamFum, Moussa Seydi, Serge P. Eholie, Edward J. Mills, Oscar Kallay, Alimuddin Zumla and Jean B. Nachega
Pages: 1184–1188
https://doi.org/10.4269/ajtmh.20-0290

 

Special issue on autonomous agents modelling other agents: Guest editorial

Posted on by

Artificial Intelligence – An International Journal
Volume 285 August 2020
https://www.sciencedirect.com/journal/artificial-intelligence/vol/285/suppl/C

 

Editorial Abstract only
Special issue on autonomous agents modelling other agents: Guest editorial
Stefano V. Albrecht, Peter Stone, Michael P. Wellman
Article 103292
Abstract
Much research in artificial intelligence is concerned with enabling autonomous agents to reason about various aspects of other agents (such as their beliefs, goals, plans, or decisions) and to utilise such reasoning for effective interaction. This special issue contains new technical contributions addressing open problems in autonomous agents modelling other agents, as well as research perspectives about current developments, challenges, and future directions.

A qualitative study on aspects of consent for genomic research in communities with low literacy

Posted on by

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 13 June 2020)

 

Research article
A qualitative study on aspects of consent for genomic research in communities with low literacy
Authors: Daima Bukini, Columba Mbekenga, Siana Nkya, Lisa Purvis, Sheryl McCurdy, Michael Parker and Julie Makani
Content type: Research article
12 June 2020
Background
Low literacy of study participants in Sub – Saharan Africa has been associated with poor comprehension during the consenting process in research participation. The concerns in comprehension are far greater when consenting to participate in genomic studies due to the complexity of the science involved. While efforts are made to explore possibilities of applying genomic technologies in diseases prevalent in Sub Saharan Africa, we ought to develop methods to improve participants’ comprehension for genomic studies. The purpose of this study was to understand different approaches that can be used to seek consent from individuals with low literacy in Sub-Saharan African countries in genomic research to improve comprehension.

Estimating the contribution of different age strata to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study

Posted on by

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 13 June 2020)

 

Estimating the contribution of different age strata to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study
Herd protection through interruption of transmission has contributed greatly to the impact of pneumococcal conjugate vaccines (PCVs) and may enable the use of cost-saving reduced dose schedules. To aid PCV age…
Authors: Stefan Flasche, Marc Lipsitch, John Ojal and Amy Pinsent
Citation: BMC Medicine 2020 18:129
Content type: Research article
Published on: 10 June 2020

High level of vaccination and protection against hepatitis B with low rate of HCV infection markers among hospital health care personnel in north of Iran: a cross-sectional study

Posted on by

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 13 June 2020)

 

High level of vaccination and protection against hepatitis B with low rate of HCV infection markers among hospital health care personnel in north of Iran: a cross-sectional study
hepatitis B virus (HBV) and C virus (HCV) are among the leading causes of mortality worldwide. Health care personnel (HCP) are subjected to increased risk of these infections. Therefore, HBV vaccination and po…
Authors: Saffar Hiva, Khoshayand Negar, Parsaei Mohammad-Reza, Ghorbani Gholam-Reza, Aarabi Mohsen, Nadi Ghara Ali-Asghar and Saffar Mohammed-Jafar
Citation: BMC Public Health 2020 20:920
Content type: Research article
Published on: 12 June 2020

Timely completion of vaccination and its determinants among children in northwest, Ethiopia: a multilevel analysis

Posted on by

BMC Public Health
http://bmcpublichealth.biomedcentral.com/articles
(Accessed 13 June 2020)

 

Timely completion of vaccination and its determinants among children in northwest, Ethiopia: a multilevel analysis
Timely vaccination is key to prevent unnecessary childhood mortality from vaccine-preventable diseases. Despite the substantial efforts to improve vaccination completeness, the effort towards timeliness of vac…
Authors: Zeleke Abebaw Mekonnen, Kassahun Alemu Gelaye, Martin C. Were and Binyam Tilahun
Citation: BMC Public Health 2020 20:908
Content type: Research article
Published on: 11 June 2020

Use of Real-world Data for New Drug Applications and Line Extensions

Posted on by

Clinical Therapeutics
May 2020 Volume 42, Issue 5, p729-958, e87-e100
http://www.clinicaltherapeutics.com/current

 

Review
Use of Real-world Data for New Drug Applications and Line Extensions
Winona R. Bolislis, Myriam Fay, Thomas C. Kühler
p926–938
Published online: April 24, 2020
Purpose
For this article, the authors compiled, summarized, and analyzed data from 27 cases in which real-world data (RWD) were applied in regulatory approval. The aims were to provide an overview of RWD, based on classifications per therapeutic area, age group, drivers of acceptability, utility, data sources, and timelines, and to present insights on how it has been applied in regulatory decision making to date.

Parental education associated with immune function in adolescence

Posted on by

The European Journal of Public Health
Volume 30, Issue 3, June 2020
https://academic.oup.com/eurpub/issue/30/3

 

Child and adolescent health
Parental education associated with immune function in adolescence
Isaac Barroso, Maria Cabral, Elisabete Ramos, João T Guimarães
European Journal of Public Health, Volume 30, Issue 3, June 2020, Pages 444–448, https://doi.org/10.1093/eurpub/ckz229

European Union initiatives in child immunization—the need for child centricity, e-health and holistic delivery

Posted on by

The European Journal of Public Health
Volume 30, Issue 3, June 2020
https://academic.oup.com/eurpub/issue/30/3

 

European Union initiatives in child immunization—the need for child centricity, e-health and holistic delivery
Michael J Rigby, Catherine E Chronaki, Shalmali S Deshpande, Peter Altorjai, Maria Brenner …
European Journal of Public Health, Volume 30, Issue 3, June 2020, Pages 449–455, https://doi.org/10.1093/eurpub/ckz199

How do Twitter users react to TV broadcasts dedicated to vaccines in Italy?

Posted on by

The European Journal of Public Health
Volume 30, Issue 3, June 2020
https://academic.oup.com/eurpub/issue/30/3

 

Infectious diseases
How do Twitter users react to TV broadcasts dedicated to vaccines in Italy?
Francesco Gesualdo, Angelo D’Ambrosio, Eleonora Agricola, Luisa Russo, Ilaria Campagna …
European Journal of Public Health, Volume 30, Issue 3, June 2020, Pages 510–515, https://doi.org/10.1093/eurpub/ckaa022

Will the Higher-Income Country Blueprint for COVID-19 Work in Low- and Lower Middle-Income Countries?

Posted on by

Global Health: Science and Practice (GHSP)
2020 | Volume 8 | Number 2
http://www.ghspjournal.org/content/current

 

EDITORIAL COMMENTARY
Will the Higher-Income Country Blueprint for COVID-19 Work in Low- and Lower Middle-Income Countries?
Stephen Hodgins,a Abdulmumin Saadb
Key Message
Strategies currently pursued in high-income and upper middle-income countries—aimed at radically suppressing incidence of COVID-19—may be unrealistic and counterproductive in most low- and lower middle-income countries. Instead, strategies need to be tailored to the setting, balancing expected benefits, potential harms, and feasibility.

From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons?

Posted on by

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 13 June 2020]

 

From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons?
It is often said that it takes 17 years to move medical research from bench to bedside. In a coronavirus disease (COVID-19) world, such time-lags feel intolerable. In these extraordinary circumstances could ye…
Authors: Stephen R. Hanney, Steven Wooding, Jon Sussex and Jonathan Grant
Citation: Health Research Policy and Systems 2020 18:61
Content type: Commentary
Published on: 8 June 2020

Building vaccine acceptance through communication and advocacy

Posted on by

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 16, Issue 5, 2020
http://www.tandfonline.com/toc/khvi20/current

 

Special Issue: Vaccine Acceptance
Editorials
Building vaccine acceptance through communication and advocacy
Kristen A. Feemster
Pages 1004-1006 | Published online: 13 May 2020
…Conclusion
The key issues for increasing the number of vaccinated people worldwide, especially children, is to increase the supply of available vaccines, assure funding and affordability for lower-income countries, improve distribution and storage networks, assure the availability of healthcare workers to administer vaccines, improve the ability of the population to access vaccination centers, and minimize refusal / hesitation to maximize acceptability of vaccines.
It is noteworthy that among these key issues, all involve physical activities except for the final issue, which is the subject of this Special Issue. Vaccine acceptance / hesitation / refusal is unique in being a state of mind for the potential vaccinee or caregiver, such that different methods must be applied to improve acceptability. The ability of workers in the field to improve acceptability will be directly reflected in increased vaccinations with concomitant reductions in morbidity and mortality from vaccine-preventable diseases. This is a major public health challenge for the coming decade and beyond, which also will be very important for the success of new vaccines in the development pipeline.

SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults

Posted on by

JAMA
June 9, 2020, Vol 323, No. 22, Pages 2231-2350
https://jamanetwork.com/journals/jama/currentissue

 

Research Letter
SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults
Uri Hamiel, MD; Eran Kozer, MD; Ilan Youngster, MD, MMSc
free access has active quiz
JAMA. 2020;323(22):2340-2341. doi:10.1001/jama.2020.8189
This cohort study compares rates of coronavirus PCR test positivity among Israelis with symptoms suspicious for COVID-19 who did and did not receive BCG vaccination as part of routine childhood immunization in the early 1980s.

Privileges and Immunity Certification During the COVID-19 Pandemic

Posted on by

JAMA
June 9, 2020, Vol 323, No. 22, Pages 2231-2350
https://jamanetwork.com/journals/jama/currentissue

 

COVID-19: Beyond Tomorrow
Privileges and Immunity Certification During the COVID-19 Pandemic
Mark A. Hall, JD; David M. Studdert, LLB, ScD
free access has active quiz
JAMA. 2020;323(22):2243-2244. doi:10.1001/jama.2020.7712
This Viewpoint explains the ethics of implementing licensing or certification of coronavirus immunity as basis for permitting public activities, anticipates challenges to effectively implementing such a system, and proposes potential policy solutions.

The Ethics of COVID-19 Immunity-Based Licenses (“Immunity Passports”)

Posted on by

JAMA
June 9, 2020, Vol 323, No. 22, Pages 2231-2350
https://jamanetwork.com/journals/jama/currentissue

 

Viewpoint
COVID-19: Beyond Tomorrow
The Ethics of COVID-19 Immunity-Based Licenses (“Immunity Passports”)
Govind Persad, JD, PhD; Ezekiel J. Emanuel, MD, PhD
free access has active quiz has multimedia has audio
JAMA. 2020;323(22):2241-2242. doi:10.1001/jama.2020.8102
This Viewpoint explains the ethical basis for implementing immunity-based licensing—certification of coronavirus immunity as a basis for permitting public activities—and anticipates challenges to effective implementing such a system, and potential solutions.
Audio Interview: Immunity Passports in the Time of COVID-19

 

COVID-19 and Postinfection Immunity -Limited Evidence, Many Remaining Questions

Posted on by

JAMA
June 9, 2020, Vol 323, No. 22, Pages 2231-2350
https://jamanetwork.com/journals/jama/currentissue

 

COVID-19: Beyond Tomorrow
COVID-19 and Postinfection Immunity -Limited Evidence, Many Remaining Questions
Robert D. Kirkcaldy, MD, MPH; Brian A. King, PhD, MPH; John T. Brooks, MD
free access
JAMA. 2020;323(22):2245-2246. doi:10.1001/jama.2020.7869
This Viewpoint describes what is currently known about the immune response to coronavirus disease 2019 (COVID-19), highlights important gaps in knowledge, and identifies opportunities for future research.

When Should Clinicians Act on Non–Statistically Significant Results From Clinical Trials?

Posted on by

JAMA
June 9, 2020, Vol 323, No. 22, Pages 2231-2350
https://jamanetwork.com/journals/jama/currentissue

 

When Should Clinicians Act on Non–Statistically Significant Results From Clinical Trials?
Paul J. Young, PhD, MBChB; Christopher P. Nickson, MBChB; Anders Perner, MD, PhD
has audio
JAMA. 2020;323(22):2256-2257. doi:10.1001/jama.2020.3508
This Viewpoint discusses considerations that might lead physicians to change their practice based on RCTs reporting non–statistically significant differences in primary outcomes, including trial methodology, totality of evidence, cost, invasiveness, and labor-intensiveness of the interventions being compared.
Audio Interview: When Should Physicians Act on Non–Statistically Significant Results From Clinical Trials?

A glossary of theories for understanding power and policy for health equity

Posted on by

Journal of Epidemiology & Community Health
June 2020 – Volume 74 – 6
https://jech.bmj.com/content/74/6

 

Glossary
A glossary of theories for understanding power and policy for health equity (20 March, 2020)
Patrick Harris, patrick.harris@unsw.edu.au
Fran Baum, Sharon Friel, Tamara Mackean, Ashley Schram, Bel Townsend
Abstract
Progressing public policies that improve health equity requires understanding and addressing the creation, use and distribution of power. This glossary provides an overview of some of the most relevant conceptualisations of the dynamics of power in policy with implications for health equity. The aim is to provide an accessible overview of the different theories and perspectives behind power for public health focused policy researchers and advocates. The Glossary demonstrates how the broad literature on power in policy deepens understanding of the institutional dynamics that creates and maintains health inequities.

What Is the Evidence to Support a Correlate of Protection for Measles? A Systematic Review

Posted on by

Journal of Infectious Diseases
Volume 221, Issue 10, 15 May 2020,
https://academic.oup.com/jid/issue/221/10

 

REVIEWS
Editor’s Choice
What Is the Evidence to Support a Correlate of Protection for Measles? A Systematic Review
Shelly Bolotin, Stephanie L Hughes, Nazish Gul, Sumaiya Khan, Paul A Rota …
The Journal of Infectious Diseases, Volume 221, Issue 10, 15 May 2020, Pages 1576–1583, https://doi.org/10.1093/infdis/jiz380
Our study reviews and evaluates the scientific literature upon which the commonly used 120 mIU/mL measles threshold of protection is based. Our findings suggest that further work is required to characterize the measles immunity threshold.

Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Posted on by

The Lancet
Jun 13, 2020 Volume 395 Number 10240 p1813-1882, e102-e106
https://www.thelancet.com/journals/lancet/issue/current

Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
The Lancet Editors

 

Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Posted on by

The Lancet
Jun 13, 2020 Volume 395 Number 10240 p1813-1882, e102-e106
https://www.thelancet.com/journals/lancet/issue/current

Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
The Lancet Editors

 

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Posted on by

The Lancet
Jun 13, 2020 Volume 395 Number 10240 p1813-1882, e102-e106
https://www.thelancet.com/journals/lancet/issue/current

 

Articles
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Feng-Cai Zhu, et al,
Interpretation
The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination. Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and rapid specific T-cell responses were noted from day 14 post-vaccination. Our findings suggest that the Ad5 vectored COVID-19 vaccine warrants further investigation.

The online competition between pro- and anti-vaccination views

Posted on by

Nature
Volume 582 Issue 7811, 11 June 2020
http://www.nature.com/nature/current_issue.html

 

Article | 13 May 2020
The online competition between pro- and anti-vaccination views
Insights into the interactions between pro- and anti-vaccination clusters on Facebook can enable policies and approaches that attempt to interrupt the shift to anti-vaccination views and persuade undecided individuals to adopt a pro-vaccination stance.
Neil F. Johnson, Nicolas Velásquez[…] & Yonatan Lupu

The Vaccines for Children Program at 25 — Access, Affordability, and Sustainability

Posted on by

New England Journal of Medicine
June 11, 2020 Vol. 382 No. 24
http://www.nejm.org/toc/nejm/medical-journal

 

Perspective
The Vaccines for Children Program at 25 — Access, Affordability, and Sustainability
Jason L. Schwartz, Ph.D., and James Colgrove, Ph.D., M.P.H.
The success of the Vaccines for Children program has meant that vaccine costs are seldom a major obstacle to childhood-vaccination efforts. But the program’s financial sustainability and the implications of its growth for other public health priorities are key issues.

Drug Evaluation during the Covid-19 Pandemic

Posted on by

New England Journal of Medicine
June 11, 2020 Vol. 382 No. 24
http://www.nejm.org/toc/nejm/medical-journal

 

Perspective
Drug Evaluation during the Covid-19 Pandemic
Benjamin N. Rome, M.D., and Jerry Avorn, M.D.
The search for a treatment for Covid-19 is testing our country’s ability to quickly develop, test, and deploy medications, presenting both opportunities and challenges to our drug-assessment apparatus. Several aspects of the U.S. response raise serious concerns, highlighting how the processes for evaluating and approving drugs can go awry during a public health crisis…

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Posted on by

New England Journal of Medicine
June 11, 2020 Vol. 382 No. 24
http://www.nejm.org/toc/nejm/medical-journal

 

Original Article
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Jonathan Grein, M.D., et al.
Abstract
Background
Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2.
Methods
We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day.
Results
Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation.
Conclusions
In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)

Inclusion of women susceptible to and becoming pregnant in preregistration clinical trials in low- and middle-income countries: A proposal for neglected tropical diseases

Posted on by

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 13 June 2020)

 

Inclusion of women susceptible to and becoming pregnant in preregistration clinical trials in low- and middle-income countries: A proposal for neglected tropical diseases
Monique Couderc-Pétry, Elisabeth Eléfant, Monique Wasunna, Alwyn Mwinga, Nilima A. Kshirsagar, Nathalie Strub-Wourgaft
Policy Platform | published 11 Jun 2020 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0008140

Video as a public health knowledge transfer tool in Burkina Faso: A mixed evaluation comparing three narrative genres

Posted on by

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 13 June 2020)

 

Video as a public health knowledge transfer tool in Burkina Faso: A mixed evaluation comparing three narrative genres
Catherine Hébert, Christian Dagenais, Esther Mc Sween-Cadieux, Valéry Ridde
Research Article | published 10 Jun 2020 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0008305

Monitoring inequality changes in full immunization coverage in infants in Latin America and the Caribbean

Posted on by

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en

 

8 Jun 2020
Monitoring inequality changes in full immunization coverage in infants in Latin America and the Caribbean
Original research | English
Full immunization coverage in the countries in the study shows higher-income inequality gaps that are not seen by observing national coverage only, but these differences appear to be reduced over time. Actions monitoring immunization coverage based on income inequalities should be considered for inclusion in the assessment of public health policies to appropriately reduce the gaps in immunization for infants in the lowest-income quintile.

COVID-19 and flu, a perfect storm

Posted on by

Science
12 June 2020 Vol 368, Issue 6496
http://www.sciencemag.org/current.dtl

 

Editorial
COVID-19 and flu, a perfect storm
By Edward A. Belongia, Michael T. Osterholm
Summary
The world is in uncharted waters for the 2020 respiratory virus season. For the first time in modern history, the Northern Hemisphere faces the prospect of the coronavirus disease 2019 (COVID-19) pandemic and a simultaneous epidemic of seasonal influenza. Each causes life-threatening illness and death, especially in older adults, people with chronic diseases, and other vulnerable populations. How can we prepare for this convergence?

Vaccines that use human fetal cells draw fire

Posted on by

Science
12 June 2020 Vol 368, Issue 6496
http://www.sciencemag.org/current.dtl

 

In Depth
Vaccines that use human fetal cells draw fire
By Meredith Wadman
Science12 Jun 2020 : 1170-1171 Full Access
Abortion opponents urge United States and Canada to avoid “ethically-tainted” cell lines.
Summary
Senior Catholic leaders in the United States and Canada, along with other antiabortion groups, are raising ethical objections to promising COVID-19 vaccine candidates that are manufactured using cells derived from human fetuses electively aborted decades ago. They have not sought to block government funding for the vaccines, which include two candidate vaccines that the Trump administration plans to support with an investment of up to $1.7 billion, as well as a third candidate made by a Chinese company in collaboration with Canada’s National Research Council. But in recent letters they implore the U.S. Food and Drug Administration and Canadian Prime Minister Justin Trudeau to ensure that alternatives that don’t rely on fetal cells are made available.

A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination

Posted on by

Vaccine
Volume 38, Issue 27

 

Research article Open access
A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination
Tsetsegsaihan Batmunkh, Marguerite T. Dalmau, Margad-Erdene Munkhsaikhan, Tungalagtuya Khorolsuren, … Claire von Mollendorf
Pages 4316-4324

Enabling emergency mass vaccination: Innovations in manufacturing and administration during a pandemic

Posted on by

Vaccine
Volume 38, Issue 26

 

Pages 4135-4218 (27 May 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/26
Research article Full text access
Enabling emergency mass vaccination: Innovations in manufacturing and administration during a pandemic
Divya Hosangadi, Kelsey Lane Warmbrod, Elena K. Martin, Amesh Adalja, … Nancy Connell
Pages 4167-4169